ArticleScientific reports2026
NFKB1 genetic variation and allergic rhinitis susceptibility: a study in the Chinese Han population.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Allergic rhinitis (AR), a highly prevalent inflammatory disorder of the upper respiratory tract, demonstrates strong genetic determinants. TLR6 and NFKB1 variants were genotyped to assess the associations with AR susceptibility. Blood samples from 992 AR patients and 992 matched healthy controls were collected for SNPs genotyping via Agena MassARRAY system. Associations were evaluated using logistic regression to calculate odds ratios (OR) with 95% confidence intervals (CI). Significant findings were evaluated by false positive reporting probability (FPRP) analysis (threshold = 0.2; prior probability = 0.1). Relationships between polymorphisms and clinical features were analyzed using analysis of Variance (ANOVA). NFKB1 rs230504 (p = 0.016, OR = 0.72) and rs4648052 (p = 0.011, OR = 0.85) demonstrated protective effects against AR risk. Stratified analyses revealed the risk-reducing-association of NFKB1 rs4648052 with AR occurrence in individuals ≤ 43 years, men, and those with BMI > 24 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.